Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Nature Communications|April 1, 2025
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATRHaineng Xu, Erin George, David Gallo, et al.
The Journal of Clinical Investigation|March 7, 2018
A PET imaging agent for evaluating PARP-1 expression in ovarian cancerMehran Makvandi, Austin Pantel, Lauren Schwartz, et al.
Nature Communications|July 26, 2020
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer modelsHyoung Kim, Haineng Xu, Erin George, et al.
Iscience|July 18, 2024
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and <i>CCNE1</i> amplified ovarian cancerHaineng Xu, Sarah B Gitto, Gwo-Yaw Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2023
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian CancerStephanie L Wethington, Payal D Shah, Lainie Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2012
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivoFiona Simpkins, Pedro Hevia-Paez, Jun Sun, et al.
JCI Insight|January 19, 2017
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancersErin George, Hyoung Kim, Clemens Krepler, et al.
Gynecologic Oncology|October 8, 2021
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancerPayal D Shah, Stephanie L Wethington, Cheyenne Pagan, et al.
Cell Reports. Medicine|October 8, 2021
<i>CCNE1</i> copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer modelsHaineng Xu, Erin George, Yasuto Kinose, et al.
Genome Medicine|December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparibAlan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
Pageof 8